3SBio receives SFDA approval for EPIAO high dose formulation
EPIAO is indicated as a treatment of chemotherapy-induced anemia. The Phase III active controlled, multi center and randomized trial evaluated the efficacy and safety of a weekly subcutaneous
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.